Hospira Recalls Bupivacaine Hydrochloride Injection Due to Particulate Matter
Hospira Inc. is recalling 119,600 vials of Bupivacaine Hydrochloride Injection due to the presence of visible particulate matter.
What this means for you
Highest-severity recall. Risk of serious injury or death is documented or strongly suspected. Stop using the product now and follow the agency's instructions.
Our severity reasoning: The FDA classified this recall as Class I, which meets the rubric criteria for a Critical severity score (5).
Plain-English summary
Hospira Inc. is recalling 119,600 vials of 0.75% Bupivacaine HCl Injection, USP, 7.5 mg/mL, 30 mL, Single-dose. The product is identified by NDC 0409-1165-02, Lot # 23-338-DK, and an expiration date of 11/14. The recall was initiated because of the presence of visible free-floating and partially embedded particulate matter in the glass vials.
The affected product was distributed nationwide. Bupivacaine Hydrochloride is a prescription drug used for epidural, infiltration, intracaudal, and perineural routes. The FDA has classified this recall as Class I, indicating a reasonable probability that use of the product may cause serious adverse health consequences or death.
Healthcare providers and patients should stop using the affected vials and contact Hospira Inc. for further instructions or to arrange for a return or replacement. Consumers should verify the lot number and expiration date on their medication to determine if it is affected by this recall.
The recalled product
- Product
- BUPIVACAINE HYDROCHLORIDE (BUPIVACAINE HYDROCHLORIDE)
- Brand
- BUPIVACAINE HYDROCHLORIDE
- Manufacturer
- Hospira Inc.
- Category
- Drug — Injection
- Hazard
- Affected units
- 119,600
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 23-338-DK
- Exp. 11/14
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Hospira Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · BUPIVACAINE HYDROCHLORIDE
- HighBupivacaine spinal ampules recalled nationwide over lack of sterility assurance
FDA (Drugs) · 2026-04-22
- HighBupivacaine Hydrochloride Injection Recalled Due to Manufacturing Temperature Deviations
FDA (Drugs) · 2022-06-15
- HighBupivacaine Hydrochloride Injection Recalled for Temperature Storage Deviations
FDA (Drugs) · 2022-06-15
- SevereBupivacaine and Lidocaine Injection Vials Recalled for Label Mix-Up
FDA (Drugs) · 2021-06-09
- CriticalHospira Recalls Bupivacaine Hydrochloride Vials Due to Particulate Matter
FDA (Drugs) · 2016-12-28
Same manufacturer · Hospira Inc.
See all →- CriticalHospira Recalls Dextrose Injection Syringes Due to Human Hair Particulate
FDA (Drugs) · 2017-05-31
- ModerateHospira Recalls Minibore Extension Sets Due to Solvent Occlusion
FDA (Devices) · 2017-01-18
- LowHospira Recalls Lidocaine and Dextrose Injection for Stability Failures
FDA (Drugs) · 2016-12-14
- SevereHospira Recalls Fentanyl Citrate Injection Ampules Due to Broken Tips
FDA (Drugs) · 2016-11-30
- HighHospira Symbiq Infusion Pump Recall for White Screen Safety Shutdown
FDA (Devices) · 2016-11-16
Same hazard · particulate matter
See all →- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- CriticalAmerican Regent Recalls Papaverine Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Nitroglycerin Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Cyanocobalamin Injections Due to Particulate Matter
FDA (Drugs) · 2026-08-26